Clinical trial
Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone
NCT00376324 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00376324 |
|---|---|
| Title | Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone |
| Official title | An Open-Label, Multiple-Dose Study of the Pharmacokinetics of Tigecycline in Human Bone |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy Subjects |
| Intervention type | Drug |
| Interventions | Tigecycline |
| Enrollment | 36 |
| Start date | Sep 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 14, 2006 |
| Last update posted | Jul 10, 2009 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: